Banca de DEFESA: PRISCILLA DAIANNE GONCALVES SILVA

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
STUDENT : PRISCILLA DAIANNE GONCALVES SILVA
DATE: 11/11/2024
TIME: 14:00
LOCAL: Sala de Reunião 1 / Teams da Microsoft
TITLE:

Neurovespin as an Adjuvant Therapy for Drug-Resistant Canine Epilepsy

KEY WORDS:

epileptic, seizures, peptides, antiepileptic drugs, dogs

PAGES: 100
BIG AREA: Outra
AREA: Defesa
SUMMARY:

Epilepsy is a chronic neurological disease that is most common in dogs and humans. In both species, resistance to antiepileptic medications is a problem that seriously affects quality of life. Translational medicine has been conducting new research, using dogs as a model for studying epilepsy in humans. They have developed a peptide called "Neurovespina" (NV) from a natural peptide found in the venom of social wasps native to “cerrado” of Brazil. This peptide contains neuroactives that have been tested for treating neurological and neurodegenerative diseases, and it has proven to be effective in controlling seizures. The advantages of its therapeutic use include high potency, excellent selectivity, low toxicity, and few adverse effects. In the current study, six dogs diagnosed with idiopathic epilepsy, which is of unknown cause, were selected based on Tier II criteria associated with the panel for diagnosing infectious diseases. While continuing with their regular anti-epileptic medication, the dogs were given NV at a dosage of 0.3 to 0.4ml (three times a day, subcutaneously). The frequency and severity of seizures were monitored every week for a period ranging from 6 to 54 months. Results showed no adverse effects (P > 0.9999) or changes in the electrocardiogram (P > 0.9999) and SBP (p = 0.2585) in the treated dogs and 8 dogs in the control group. The mean semiannual frequency (FMS) of seizures decreased after the use of NV in the treated group (p=0.0312 and 0.044). The main downsides of the peptide were associated with its subcutaneous (SC) administration route and frequency of use. We have determined that NV shows promise as an alternative for managing drug-resistant epilepsy. It may also serve as an option for adjuvant therapies for dogs and potentially for humans in the future. All dogs experienced an improvement in their quality of life, including a reduction in clustered seizures, status epilepticus, the post-ictus period, and/or cognitive enhancement. However, these findings emphasize the necessity for future studies to further investigate the clinical use of NV in broader populations, the transdermal administration route, and serum quantification in NV to improve dose definition.

COMMITTEE MEMBERS:
Presidente - 2567703 - MARCIA RENATA MORTARI
Interno - ***.214.781-** - GABRIEL AVOHAY ALVES CAMPOS - UnB
Interno - 1952915 - RAFAEL PLAKOUDI SOUTO MAIOR
Externo à Instituição - ROGERIO MARTINS AMORIM - UNESP